Quality of life of patients with gastrointestinal cancers undergoing chemotherapy
- PMID: 29679368
- PMCID: PMC5999562
- DOI: 10.1007/s11136-018-1860-1
Quality of life of patients with gastrointestinal cancers undergoing chemotherapy
Abstract
Purpose: Findings regarding changes in the quality of life (QOL) of patients with gastrointestinal cancers (GI) undergoing chemotherapy (CTX) are inconclusive. Purpose was to evaluate for changes in QOL scores of patients with GI cancers over two cycles of CTX.
Methods: Patients (n = 397) completed disease-specific [i.e., Quality of Life-Scale-Patient Version (QOL-PV)] and generic [12-item Medical Outcomes Study Short Form Survey (SF-12)] measures of QOL a total of six times over two cycles of CTX. Changes in these QOL scores were evaluated using bootstrapped multilevel regression with full information maximum likelihood estimation. Treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, GI cancer diagnosis (i.e., colon/rectum/anal vs. other), and CTX regimen were evaluated as covariates in the conditional models for each of the QOL scores.
Results: During the second cycle of CTX, QOL-PV scores decreased in the week following CTX administration, and then increased the following week. For both cycles of CTX, the physical component summary and mental component summary scores of the SF-12 decreased in the week following CTX administration and then increased the following week. Increased time from cancer diagnosis and a higher number of prior cancer treatments resulted in worse QOL-PV and SF-12 scores at enrollment.
Conclusions: While changes in QOL scores over the two CTX cycles were statistically significant, the differences were not clinically meaningful. Future studies need to determine the optimal timing of QOL assessments to assess changes associated with cancer treatments.
Keywords: Chemotherapy; Gastrointestinal cancer; Quality of life; Targeted therapy.
Figures

Similar articles
-
Investigation of the relationship among fatigue, self-efficacy and quality of life during chemotherapy in patients with breast, lung or gastrointestinal cancer.Eur J Cancer Care (Engl). 2019 Jan;28(1):e12898. doi: 10.1111/ecc.12898. Epub 2018 Jul 24. Eur J Cancer Care (Engl). 2019. PMID: 30039883
-
Changes in the Occurrence, Severity, and Distress of Symptoms in Patients With Gastrointestinal Cancers Receiving Chemotherapy.J Pain Symptom Manage. 2018 Mar;55(3):808-834. doi: 10.1016/j.jpainsymman.2017.10.004. Epub 2017 Oct 17. J Pain Symptom Manage. 2018. PMID: 29051114 Free PMC article.
-
Quality of Life in Women With Breast Cancer Treated With or Without Chemotherapy.Cancer Nurs. 2017 Mar/Apr;40(2):108-116. doi: 10.1097/NCC.0000000000000370. Cancer Nurs. 2017. PMID: 27070221
-
Assessment of quality of life during chemotherapy.Acta Oncol. 2001;40(2-3):175-84. doi: 10.1080/02841860151116222. Acta Oncol. 2001. PMID: 11441930 Review.
-
Changes in the quality of life: a major goal of cardiac rehabilitation.J Cardiopulm Rehabil. 2001 Jul-Aug;21(4):189-200. doi: 10.1097/00008483-200107000-00001. J Cardiopulm Rehabil. 2001. PMID: 11508178 Review.
Cited by
-
Effects of exercise by type and duration on quality of life in patients with digestive system cancers: A systematic review and network meta-analysis.J Sport Health Sci. 2023 Jul;12(4):491-500. doi: 10.1016/j.jshs.2022.12.008. Epub 2022 Dec 15. J Sport Health Sci. 2023. PMID: 36528289 Free PMC article.
-
Evaluation of Large Language Models in Tailoring Educational Content for Cancer Survivors and Their Caregivers: Quality Analysis.JMIR Cancer. 2025 Apr 7;11:e67914. doi: 10.2196/67914. JMIR Cancer. 2025. PMID: 40192716 Free PMC article.
-
Effects of a polyherbal formulation on the quality of life and survival of patients with common upper gastrointestinal cancers: A randomized placebo-controlled trial.Avicenna J Phytomed. 2021 Nov-Dec;11(6):566-575. doi: 10.22038/AJP.2021.18132. Avicenna J Phytomed. 2021. PMID: 34804894 Free PMC article.
-
5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last?Cancer Manag Res. 2021 Jan 11;13:147-161. doi: 10.2147/CMAR.S285361. eCollection 2021. Cancer Manag Res. 2021. PMID: 33469359 Free PMC article.
-
Distinct profiles of multiple co-occurring symptoms in patients with gastrointestinal cancers receiving chemotherapy.Support Care Cancer. 2021 Aug;29(8):4461-4471. doi: 10.1007/s00520-020-05946-4. Epub 2021 Jan 16. Support Care Cancer. 2021. PMID: 33454824 Free PMC article.
References
-
- Bottomley A. The cancer patient and quality of life. The Oncologist. 2002;7:120–125. - PubMed
-
- McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. Journal of Clinical Oncology. 2012;30(26):3223–3228. - PMC - PubMed
-
- Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Annals of Oncology. 2015;26(9):1846–1858. - PubMed
-
- Khanna D, Tsevat J. Health related qualtiy of life: An introduction. American Journal of Managed Care. 2007;13(9):S218–S223. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources